Patient Registry Shines Spotlight on PSVT, an Overlooked Heart Disorder

"This registry is shedding light on an underlying condition that most people never know they are at risk for until they experience a sudden PSVT attack," said Bruce Stambler, MD, FHRS, Piedmont Heart Institute, Atlanta, Ga. "Individuals with PSVT often encounter delayed or incorrect diagnosis and may be frequently labelled as having an anxiety or panic attack. Among those accurately diagnosed, up to one third never return for follow-up care, making it difficult to assess the impact of PSVT on their lives and to determine which treatments are most appropriate."

The information from the registry is intended as a resource for participants, their families, their doctors, and the research community to better understand PSVT-related symptoms, diagnosis, patient self-management, medical treatments, and the impact of PSVT on quality of life for patients.

"There have been very limited advances in the field of PSVT over the last few decades and educational resources for patients are sparse and sometimes confusing," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. "Offering this web-based community empowers patients to learn from each other and advance their own care. We want to hear from patients firsthand about the challenges of living with PSVT, so we can all better understand and meet their needs."

To learn more, visit PSVTPlaceRegistry.com or call 1-855-646-3446. To join the registry, complete a brief pre-screening questionnaire to create an online account. All participants receive generalized information about PSVT management. Participants also have the option to fill in their health information to receive access to personalized reports that track their experience with PSVT. To protect the privacy of participants, all personal information will be made anonymous in the event data is shared with scientists or medical professionals. The registry is initially open to patients in the United States and Canada, with plans for future expansion to other countries.

About Paroxysmal Supraventricular Tachycardia (PSVT)
Paroxysmal supraventricular tachycardia is a condition that afflicts approximately 1.7 million people and results in over 600,000 healthcare claims per year in the U.S. alone. During a PSVT episode, patients may feel palpitations while heart rate increases dramatically, sometimes exceeding 200 beats per minute. Although the condition is not life threatening, it causes great distress to the patient and often results in a visit to a hospital emergency department where the patient is usually administered intravenous drugs and monitored until the symptoms resolve.

About Milestone Pharmaceuticals
Milestone, headquartered in Montreal, Canada with a U.S. subsidiary in Charlotte, N.C., is a clinical stage drug development company focused on developing etripamil, a calcium channel blocker intended to provide fast-acting and short-acting treatment of PSVT episodes. For more information, visit www.milestonepharma.com.

Christine Diven
JPA Health Communications
202-591-4003
[email protected]

SOURCE Milestone Pharmaceuticals

Related Links

http://www.milestonepharma.com